Randomized controlled trialHumanClinical Trial, Phase III
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
The New England journal of medicine, 2025 Jun 12. Ji L, Jiang H, Bi Y and 21 others.
Study type
Randomized controlled trial · Clinical Trial, Phase III
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The New England journal of medicine
Published
2025 Jun 12
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultAnti-Obesity AgentsBody Mass IndexDouble-Blind MethodDrug Administration Schedule
Other papers on Mazdutide
Systematic review / meta-analysis · 2026
Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials
Randomized controlled trial · 2026Mazdutide 9 mg in Chinese adults with a body mass index ≥30 kg/m(2) but without diabetes: A phase 2 randomized controlled trial
Randomized controlled trial · 2023A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page